CALGB-30610-RTOG-0538

NCT00632853 📎

Regimen

Experimental
70 Gy once-daily thoracic radiotherapy + chemotherapy
Control
45 Gy twice-daily thoracic radiotherapy + chemotherapy

Population

Patients with limited-stage small-cell lung cancer receiving concurrent chemoradiotherapy

Key finding

mOS 30.1 mo (70-Gy QD) vs 28.5 mo (45-Gy BID); HR 0.94 (95% CI 0.76-1.17, P=0.594); 5-yr OS 32% vs 29%; 45-Gy BID remains standard

Source: PMID 36623230

Timeline

    Guideline citations

    • NCCN SCLC (p.28)
    • CSCO SCLC 2025 (p.52)⚠️ OCR source